Head and Neck Cancer

Featured

Quiz
Quiz: Cetuximab vs Cisplatin for Locoregional Control of HNSCC
True or False: In combination with radiotherapy, cisplatin is inferior to cetuximab for the locoregional control of advanced head and neck squamous cell cancer.
News
Deep Learning Models for Image-Guided RT in Head and Neck and Prostate Cancers
Machine learning models achieve clinically acceptable accuracy in image segmentation tasks in radiotherapy planning and…
News
FDA Approves Pralsetinib for Thyroid Cancers Harboring RET Alterations
The FDA granted approval to pralsetinib for patients with advanced or metastatic RET-mutant medullary thyroid cancer or…
News
Cetuximab Inferior to Cisplatin for Locoregional Control of HNSCC
In combination with radiotherapy, cetuximab is inferior to cisplatin for the locoregional control of advanced head and…
News
Feasibility of Electronic PROs During Radiotherapy for Head and Neck Cancer
Findings from a recent analysis show the collection of electronic PROs during radiotherapy is feasible for patients…

News

Deep Learning Models for Image-Guided RT in Head and Neck and Prostate Cancers
FDA Approves Pralsetinib for Thyroid Cancers Harboring RET Alterations
Cetuximab Inferior to Cisplatin for Locoregional Control of HNSCC
Feasibility of Electronic PROs During Radiotherapy for Head and Neck Cancer

Guideline Updates

NCCN Updates Clinical Practice Guideline for Thyroid Carcinomas